by qfrsolutions | Jan 27, 2017 | News
Source: Business Wire Encore Dermatology Inc., a privately held dermatology company that specializes in developing and commercializing novel prescription products for improving skin health, announced today the availability of TridesilonTM (desonide) Cream, 0.05% in a...
by qfrsolutions | Jan 26, 2017 | News
Source: Reuters U.S. healthcare giant Johnson & Johnson (JNJ.N) will buy Swiss biotech company Actelion (ATLN.S) in a $30 billion all-cash deal that includes spinning off Actelion’s research and development pipeline, the companies said on Thursday. The...
by qfrsolutions | Jan 18, 2017 | News
Source: Globe Newswire Novan, Inc. (“the Company” or “Novan”) (NOVN) today announced that the Company has entered into an exclusive license agreement with Sato Pharmaceutical Co., Ltd. (“Sato”), a Japanese company with a...
by qfrsolutions | Jan 4, 2017 | News
Source: Sun Pharma announced successful Phase 3 confirmatory clinical trial results for Seciera™ (cyclosporine A, 0.09% ophthalmic solution), for the treatment of dry eye disease. Seciera™ is a patented, novel, proprietary nanomicellar formulation of...
by qfrsolutions | Dec 14, 2016 | News
Source: Reuters The U.S. Food and Drug Administration on Wednesday said it approved Pfizer Inc’s (PFE.N) ointment to treat mild to moderate cases of the itchy skin condition eczema, or atopic dermatitis, for use in patients aged two years and older. Atopic...
by qfrsolutions | Dec 13, 2016 | News
Source: PR Newswire Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) (“Valeant” or the “Company”) today announced that William D. Humphries has been appointed Executive Vice President, Dermatology, effective January 2, 2017....
